Cargando…

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer

Gastric cancer (GC) is the second leading cause of cancer-related mortality worldwide. The usual treatment of GC consists of surgery with additional adjuvant chemotherapy. In the present study, the feasibility and safety of adjuvant S-1 plus oxaliplatin (SOX) chemotherapy for patients with GC and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	YANG, LIN, YANG, YI, QIN, QIONG, ZHOU, AIPING, ZHAO, JIANJUN, WANG, JINWAN, SHU, CHANG, YUAN, XINGHUA, HU, SONGNIAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315063/ https://www.ncbi.nlm.nih.gov/pubmed/25663930 http://dx.doi.org/10.3892/ol.2014.2821

Ejemplares similares

CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients
por: Yang, Lin, et al.
Publicado: (2017)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2022)

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
por: Jiang, Zhichao, et al.
Publicado: (2020)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer
por: Ahn, Geon Tae, et al.
Publicado: (2020)

Optimal Duration of Adjuvant Chemotherapy for Gastric Cancer: Might Less Be More?
por: Han, Hye Sook
Publicado: (2022)

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
por: Wang, Guoxiu, et al.
Publicado: (2018)

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer
por: Qu, Jing-lei, et al.
Publicado: (2013)

Updated Adjuvant Chemotherapy for Gastric Cancer
por: Takayama, Toshizo, et al.
Publicado: (2023)

Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients
por: Su, Jian-wei, et al.
Publicado: (2022)

Update of Adjuvant Chemotherapy for Resected Gastric Cancer
por: Oh, Sang Cheul
Publicado: (2012)

Actual compliance to adjuvant chemotherapy in gastric cancer
por: Kim, Dong-Wook, et al.
Publicado: (2019)

Current status of adjuvant chemotherapy for gastric cancer
por: Kim, In-Hwan
Publicado: (2019)

Is adjuvant chemotherapy necessary for early gastric cancer?
por: Mei, Yu, et al.
Publicado: (2022)

Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer
por: Tao, Qing, et al.
Publicado: (2020)

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
por: Collienne, Maike, et al.
Publicado: (2020)

Glioma SOX2 expression decreased after adjuvant therapy
por: Yu, Wei, et al.
Publicado: (2019)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer
por: Li, Zhu, et al.
Publicado: (2017)

Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer: a propensity-matched analysis
por: Quan, RenCui, et al.
Publicado: (2016)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer
por: Chen, Yi-Fu, et al.
Publicado: (2023)

Risk Factors for Discontinuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
por: Kawazoe, Hitoshi, et al.
Publicado: (2015)

Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer
por: Lichthardt, Sven, et al.
Publicado: (2016)

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer
por: Chang, Alex Yuang-Chi, et al.
Publicado: (2016)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival
por: Jiang, Zhi-Nong, et al.
Publicado: (2021)

The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer
por: Yang, Yuchong, et al.
Publicado: (2023)

The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study
por: Zhang, Chenghai, et al.
Publicado: (2022)

An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer
por: Wang, Jia-Bin, et al.
Publicado: (2020)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Single‐cell Suspension Assay with an MTT End Point Is Useful for Evaluating the Optimal Adjuvant Chemotherapy for Advanced Gastric Cancer
por: Saikawa, Yoshiro, et al.
Publicado: (1994)

The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer
por: Abbas, Hamza, et al.
Publicado: (2011)

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
por: Chen, Jun-Bing, et al.
Publicado: (2022)

SOX11: friend or foe in tumor prevention and carcinogenesis?
por: Yang, Zhi, et al.
Publicado: (2019)

Traditional Chinese Medicine Enhances Survival in Patients with Gastric Cancer after Surgery and Adjuvant Chemotherapy in Taiwan: A Nationwide Matched Cohort Study
por: Shih, Wei-Tai, et al.
Publicado: (2021)

Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis
por: Zhao, Jun-hua, et al.
Publicado: (2016)

Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
por: Hisashige, Akinori, et al.
Publicado: (2013)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Effect of laparoscopic gastrectomy on compliance with adjuvant chemotherapy in patients with gastric cancer
por: Bao, Huizheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ffchnsppubb0gpm2500on06grp